aztreonam has been researched along with Gram-Negative Bacterial Infections in 39 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Gram-Negative Bacterial Infections: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of aztreonam in combination with vancomycin was compared with that of gentamicin plus piperacillin as empirical antibiotic treatment for fever in 61 neutropenic patients." | 9.07 | Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study. ( Kelsey, SM; Newland, AC; Shaw, E, 1992) |
| "The efficacy of aztreonam in combination with vancomycin was compared with that of gentamicin plus piperacillin as empirical antibiotic treatment for fever in 61 neutropenic patients." | 5.07 | Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study. ( Kelsey, SM; Newland, AC; Shaw, E, 1992) |
| "MICs and biofilm inhibitory concentrations (BICs) were measured for 68 cystic fibrosis (CF) Achromobacter isolates for amikacin, aztreonam, colistin, levofloxacin, and tobramycin." | 3.83 | Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients. ( Beaudoin, T; LiPuma, JJ; Tom, SK; Waters, V; Yau, YC, 2016) |
| " In nonneutropenic patients believed to be at increased risk for renal dysfunction, aztreonam is a less toxic alternative to aminoglycoside therapy for treatment of suspected aerobic gram-negative infection." | 2.67 | Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. ( Lerner, SA; Levine, DP; Moore, RD, 1992) |
| " Of particular interest are the pharmacokinetic and pharmacodynamic properties of aztreonam alone and in combination with β-lactamase inhibitors." | 2.53 | A review of the pharmacokinetics and pharmacodynamics of aztreonam. ( MacGowan, AP; Ramsey, C, 2016) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that is active exclusively against the aerobic gram-negative bacilli." | 2.39 | Aztreonam. ( Cunha, BA; Johnson, DH, 1995) |
| "Aztreonam was not active against most Enterobacteriaceae isolates producing class A or class C enzymes alone or in combination with class B metallo-β-lactamases." | 1.42 | In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. ( Biedenbach, DJ; Bouchillon, SK; Bradford, PA; Kazmierczak, K; Sahm, DF, 2015) |
| "Aztreonam-avibactam was active against all β-lactamase producers (including producers of NDM-1 and IMP-4/8) except blaOXA-containing Acinetobacter baumannii and some Pseudomonas aeruginosa isolates." | 1.40 | In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. ( Chen, H; He, W; Li, H; Nichols, WW; Testa, R; Wang, H; Wang, Q; Wang, X; Wang, Z; Zhang, F; Zhao, C, 2014) |
| " All patients had received at least two aztreonam doses before the dosage interval being studied." | 1.30 | Pharmacokinetics of aztreonam in critically ill surgical patients. ( Asensio, J; Belzberg, H; Berne, TV; Cornwell, EE; Demetriades, D; Gill, MA; Kern, JW; Theodorou, D; Yu, W, 1997) |
| "Aztreonam is a monobactam antibiotic with similar pharmacokinetic and microbiologic activity to that of ceftazidime." | 1.30 | Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. ( Burgess, DS; Hardin, TC; Summers, KK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 16 (41.03) | 18.2507 |
| 2000's | 4 (10.26) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| De Almeida Torres, N | 1 |
| Morales Junior, R | 1 |
| Bueno Lopes, LF | 1 |
| Zeigler, R | 1 |
| Everson Uip, D | 1 |
| Lin, Q | 1 |
| Zou, H | 1 |
| Chen, X | 1 |
| Wu, M | 1 |
| Ma, D | 1 |
| Yu, H | 1 |
| Niu, S | 1 |
| Huang, S | 1 |
| Wenzler, E | 1 |
| Deraedt, MF | 1 |
| Harrington, AT | 1 |
| Danizger, LH | 1 |
| Tamma, PD | 1 |
| Hsu, AJ | 1 |
| Mojica, MF | 2 |
| Rutter, JD | 1 |
| Taracila, M | 1 |
| Abriata, LA | 1 |
| Fouts, DE | 1 |
| Papp-Wallace, KM | 1 |
| Walsh, TJ | 1 |
| LiPuma, JJ | 2 |
| Vila, AJ | 1 |
| Bonomo, RA | 2 |
| Wang, X | 1 |
| Zhang, F | 1 |
| Zhao, C | 1 |
| Wang, Z | 1 |
| Nichols, WW | 1 |
| Testa, R | 1 |
| Li, H | 1 |
| Chen, H | 1 |
| He, W | 1 |
| Wang, Q | 1 |
| Wang, H | 1 |
| Biedenbach, DJ | 1 |
| Kazmierczak, K | 1 |
| Bouchillon, SK | 1 |
| Sahm, DF | 1 |
| Bradford, PA | 1 |
| Kennedy, H | 1 |
| Wilson, S | 1 |
| Marwick, C | 1 |
| Malcolm, W | 1 |
| Nathwani, D | 1 |
| Tom, SK | 1 |
| Yau, YC | 1 |
| Beaudoin, T | 1 |
| Waters, V | 1 |
| Fu, HG | 1 |
| Hu, XX | 1 |
| Li, CR | 1 |
| Li, YH | 1 |
| Wang, YX | 1 |
| Jiang, JD | 1 |
| Bi, CW | 1 |
| Tang, S | 1 |
| You, XF | 1 |
| Song, DQ | 1 |
| Ramsey, C | 1 |
| MacGowan, AP | 1 |
| Ouellette, CP | 1 |
| Leber, A | 1 |
| Becknell, MB | 1 |
| Ardura, MI | 1 |
| Perez, F | 1 |
| Shimamura, M | 1 |
| Aitken, SL | 1 |
| Shelburne, SA | 1 |
| Bador, J | 1 |
| Amoureux, L | 1 |
| Duez, JM | 1 |
| Drabowicz, A | 1 |
| Siebor, E | 1 |
| Llanes, C | 1 |
| Neuwirth, C | 1 |
| Shakil, S | 1 |
| Azhar, EI | 1 |
| Tabrez, S | 1 |
| Kamal, MA | 1 |
| Jabir, NR | 1 |
| Abuzenadah, AM | 1 |
| Damanhouri, GA | 1 |
| Alam, Q | 1 |
| Hewer, SL | 1 |
| Patel, KM | 1 |
| Svestka, M | 1 |
| Sinkin, J | 1 |
| Ruff, P | 1 |
| Dudley, MN | 1 |
| Ambrose, PG | 1 |
| Bhavnani, SM | 1 |
| Craig, WA | 1 |
| Ferraro, MJ | 1 |
| Jones, RN | 1 |
| Frei, CR | 1 |
| Burgess, DS | 2 |
| Shibl, AM | 2 |
| Ishag, AH | 1 |
| Durgham, SM | 1 |
| Sklavunu-Tsurutsoglu, S | 1 |
| Gatzola-Karaveli, M | 1 |
| Hatziioannidis, K | 1 |
| Tsurutsoglu, G | 1 |
| Honderlick, P | 1 |
| Gravisse, J | 1 |
| Dardelle, D | 1 |
| Cahen, P | 1 |
| Gospodarek, E | 1 |
| Gierlotka, K | 1 |
| Deptuła, A | 1 |
| Michalska, A | 1 |
| Castelao, AM | 1 |
| Soto, K | 1 |
| Grinyó, JM | 1 |
| Gilvernet, S | 1 |
| Serón, D | 1 |
| Torras, J | 1 |
| Riera, L | 1 |
| Cruzado, JM | 1 |
| Alsina, J | 1 |
| Goya, T | 1 |
| Torisu, M | 1 |
| Doi, F | 1 |
| Yoshida, T | 1 |
| Wang, JX | 1 |
| Liu, YN | 1 |
| Johnson, DH | 1 |
| Cunha, BA | 2 |
| Chong, Y | 1 |
| Lee, K | 1 |
| Kwon, OH | 1 |
| Zemelman, R | 1 |
| Bello, H | 1 |
| Dominguez, M | 1 |
| Gonzalez, G | 1 |
| Mella, S | 1 |
| Garcia, A | 1 |
| Navarro, F | 1 |
| Alonso, C | 1 |
| Ballús, J | 1 |
| Miró, E | 1 |
| March, F | 1 |
| Coll, P | 1 |
| Mirelis, B | 1 |
| Cornwell, EE | 1 |
| Belzberg, H | 1 |
| Berne, TV | 1 |
| Gill, MA | 1 |
| Theodorou, D | 1 |
| Kern, JW | 1 |
| Yu, W | 1 |
| Asensio, J | 1 |
| Demetriades, D | 1 |
| García Sánchez, JE | 1 |
| Vazquez López, ML | 1 |
| Blazquez de Castro, AM | 1 |
| Perez Simon, JA | 1 |
| Gutierrez, NG | 1 |
| Martin, IT | 1 |
| García-Rodríguez, JA | 1 |
| Summers, KK | 1 |
| Hardin, TC | 1 |
| Downhour, NP | 1 |
| Petersen, EA | 1 |
| Krueger, TS | 1 |
| Tangella, KV | 1 |
| Nix, DE | 1 |
| Bosi, A | 1 |
| Fanci, R | 1 |
| Pecile, P | 1 |
| Guidi, S | 1 |
| Saccardi, R | 1 |
| Vannucchi, AM | 1 |
| Longo, G | 1 |
| Donnini, E | 1 |
| Orsi, A | 1 |
| Rossi-Ferrini, P | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Moore, RD | 1 |
| Lerner, SA | 1 |
| Levine, DP | 1 |
| Kelsey, SM | 1 |
| Shaw, E | 1 |
| Newland, AC | 1 |
| Ladefoged, J | 1 |
8 reviews available for aztreonam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Cef | 2019 |
A review of the pharmacokinetics and pharmacodynamics of aztreonam.
Topics: Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Clinical Trials as Topic; Drug Therapy, Combi | 2016 |
New Delhi metallo-β-lactamase (NDM-1): an update.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitor | 2011 |
Inhaled antibiotics in cystic fibrosis: what's new?
Topics: Administration, Inhalation; Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Child, Pr | 2012 |
Ciprofloxacin-resistant Aeromonas hydrophila infection following leech therapy: a case report and review of the literature.
Topics: Aeromonas hydrophila; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aztreonam; Ciprofloxacin; Drug | 2013 |
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacterial Infect | 2013 |
Aztreonam.
Topics: Aztreonam; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 1995 |
Aztreonam.
Topics: Aztreonam; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Urinary Tract | 1993 |
6 trials available for aztreonam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Prophylaxis of urinary tract infection in renal transplantation: comparison of three different protocols using ceftriaxone-cloxacillin, aztreonam-cloxacillin, or aztreonam-amoxycillin-clavulanic acid.
Topics: Adult; Amoxicillin; Aztreonam; Ceftriaxone; Cloxacillin; Drug Therapy, Combination; Female; Follow-U | 1995 |
Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study.
Topics: Aztreonam; Bone Marrow Transplantation; Colistin; Digestive System Diseases; Drug Therapy, Combinati | 1992 |
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Auditory Threshold; Aztreonam; Bilirubin; Creatinine; Double | 1992 |
Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study.
Topics: Adult; Aztreonam; Bacteremia; Drug Therapy, Combination; Fever; Gentamicins; Gram-Negative Bacteria; | 1992 |
Aztreonam for renal graft pyelonephritis.
Topics: Adult; Ampicillin; Aztreonam; Female; Gram-Negative Bacterial Infections; Humans; Kidney Transplanta | 1991 |
25 other studies available for aztreonam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Diabetes Mellitus, Type 2; Drug | 2023 |
Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Ceftazidime; Drug Combinations; Drug Resista | 2021 |
Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Drug Combinati | 2017 |
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; | 2019 |
In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.
Topics: Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; China; Drug Combinations; Drug Resist | 2014 |
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Dr | 2015 |
Reduction in broad-spectrum Gram-negative agents by diverse prescribing of aztreonam within NHS Tayside.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Drug Prescriptions; Drug Utilization; Gram-Negative Bacteri | 2015 |
Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.
Topics: Achromobacter; Amikacin; Anti-Bacterial Agents; Aztreonam; Biofilms; Colistin; Cystic Fibrosis; Gram | 2016 |
Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.
Topics: Anti-Bacterial Agents; Aztreonam; Drug Design; Escherichia coli; Gram-Negative Bacteria; Gram-Negati | 2016 |
Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; beta-Lactamases; Ceftazidime; Co | 2016 |
First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.
Topics: Achromobacter denitrificans; Aztreonam; Bacterial Outer Membrane Proteins; Cephalosporins; Chloramph | 2011 |
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Computer Simu | 2005 |
Comparative in-vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
Topics: Anti-Bacterial Agents; Aztreonam; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 1989 |
Aztreonam treatment of neonatal sepsis.
Topics: Anti-Bacterial Agents; Aztreonam; Birth Weight; Gram-Negative Bacterial Infections; Humans; Infant; | 1989 |
[Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
Topics: Anti-Bacterial Agents; Aztreonam; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Ha | 2007 |
[Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; Carbapenems; Colistin; Cross Infection; Dr | 2007 |
Effects of granulocyte colony stimulating factor and monobactam antibiotics (Aztreonam) on neutrophil functions in sepsis.
Topics: Animals; Aztreonam; Cell Adhesion; Chemotaxis, Leukocyte; Coloring Agents; Gram-Negative Bacterial I | 1993 |
[Antibiotic treatment for pneumonia caused by Flavobacterium meningosepticum].
Topics: Aged; Aztreonam; Cefsulodin; Ciprofloxacin; Drug Therapy, Combination; Female; Flavobacterium; Gram- | 1994 |
In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Doxycycline; Enterobact | 1993 |
Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chile; Ciprofloxacin; Cross Infection; Drug Resist | 1993 |
[Clinical relevance of gram-negative bacteria having inducible chromosomic beta-lactamase at an intensive care unit].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; beta-Lactamases; Cephalosporin Resistance; Ch | 1996 |
Pharmacokinetics of aztreonam in critically ill surgical patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Critical Illness; Female; Gram-Negative Bacte | 1997 |
Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports.
Topics: Adult; Aged; Aztreonam; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Multiple; Drug Therapy, | 1997 |
Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Topics: Adolescent; Adult; Aztreonam; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Ha | 1999 |
Severe cellulitis/myositis caused by Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Aztreonam; Bone Marrow Transplantation; Cellulitis; Clavulanic Acid; Drug The | 2002 |